Home
HelpTest ID ANAR Antinuclear Antibodies (ANA), IFA with Reflex to Connective Tissue Disease Antibodies
Useful For
Evaluation of patients with signs and symptoms compatible with connective tissue diseases
The testing algorithm is useful in the initial evaluation of patients and performs best in clinical situations in which the prevalence of disease is low.
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| ANAH2 | Antinuclear Ab, HEp-2 Substrate, S | Yes | Yes |
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| ANAB | Antinuclear Antibody (Multiple), S | No | No |
| ADNA | DNA Double-Stranded Ab, IgG, S | Yes | No |
| RIB | Ribosome P Ab, IgG, S | Yes | No |
| ENAE | Ab to Extractable Nuclear Ag Eval,S | Yes | No |
Testing Algorithm
If antinuclear antibodies (ANA) HEp-2 substrate screen is positive, then ANA multiple will be performed at an additional charge.
If ANAB is <1:160, the cascade will stop and results will be reported.
If ANAB is ≥1:160, then DNA double-stranded antibody, ribosome P antibody, and antibody to extractable nuclear antibody will be performed at an additional charge.
Special Instructions
Method Name
Immunofluorescence Assay (IFA)
Reporting Name
ANA Reflex to CTD Ab, SSpecimen Type
SerumContainer/Tube:
Preferred: Red top
Acceptable: Serum gel
Specimen Volume: 1 mL
Specimen Minimum Volume
.6 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 14 days |
| Frozen | 14 days |
Clinical Information
Antinuclear antibodies (ANA) occur in patients with various autoimmune diseases, both systemic and organ specific, but they are particularly common in systemic rheumatic diseases (SRD). The SRDs include systemic lupus erythematosus (SLE), discoid lupus erythematosus, drug-induced lupus erythematosus, mixed connective tissue disease, Sjogren syndrome, scleroderma (systemic sclerosis), CREST syndrome (calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia), rheumatoid arthritis, and polymyositis or dermatomyositis.
|
Autoantibodies with High Specificity for Individual Connective Tissue Diseases |
|
|
dsDNA antibodies |
SLE |
|
Scl 70 antibodies (topoisomerase 1) |
Scleroderma |
|
Jo 1 antibodies (histidyl tRNA synthetase) |
Polymyositis |
|
SSA/Ro and SSB/La antibodies |
Sjogren syndrome |
|
RNP antibodies (in isolation) |
MCTD |
|
Sm antibodies |
SLE |
|
Ribosome P antibodies |
SLE |
Low titers of ANA reactivity are observed in approximately 5% of apparently healthy individuals and the incidence increases with increasing age. Titers ≥1:160 are generally considered to be clinically significant and more closely related to the presence of active disease. The results of this test must be interpreted in the context of the clinical picture.
Reference Values
<1:40 (Negative)
Cautions
This test is a laboratory diagnostic aid and by itself is not diagnostic. Positive results of this test may occur in apparently healthy people. Therefore, the results of this test must be interpreted by a medical authority in the context of the patient's total clinical condition.
Day(s) Performed
Monday through Friday
Report Available
1 day/2 days if positivePerforming Laboratory
Mayo Medical Laboratories in New England
CPT Code Information
86038-Antinuclear Antibodies (ANA), HEp-2
83516-Ribosome P Antibodies (if appropriate)
86039-Antinuclear Antibody (Multiple) (if appropriate)
86225-DNA Double-Stranded (dsDNA) Antibodies (if appropriate)
86235 x 6-Antibody to Extractable Nuclear Antigen Evaluation (if appropriate)